Patents by Inventor Tatsushi TODA

Tatsushi TODA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210319080
    Abstract: Provided is a tensor data calculation device that includes a matrix product calculation processor and decomposes N-th order (N is an integer of 2 or more) non-negative tensor data into N factor matrices by factorization. The tensor data calculation device includes: a factorization means that represents update formulae of the factor matrices for optimizing a prescribed objective function value in a format that includes a matrix product of a first matrix obtained by expanding other N?1 factor matrices other than the factor matrices by a Kronecker product and a second matrix defined by a tensor product of the non-negative tensor data and the N factor matrices and calculate the update formulae; and a matrix calculation means that calculates the matrix products included in the update formulae with the aid of the matrix product calculation processor. The factorization means calculates the update formulae using calculation results of the matrix products calculated by the matrix calculation means.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 14, 2021
    Inventors: Tatsushi MATSUBAYASHI, Ryota IMAI, Masahiro KOZIMA, Hiroyuki TODA
  • Publication number: 20210272453
    Abstract: An object is to make it possible to learn a prediction model for precisely predicting the number of passersby at a prediction time point. A learning unit 300 learns parameters of the prediction model with respect to each of a plurality of observation points based on learning data such that the number of passersby at the observation point at a prediction time point predicted using the prediction model matches the number of passersby at a time point corresponding to the prediction time point included in the learning data. The learning data includes, with respect to each observation point, a past time point of the observation point and the number of passersby at the observation point at the past time point.
    Type: Application
    Filed: July 8, 2019
    Publication date: September 2, 2021
    Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Koshin TO, Tatsushi MATSUBAYASHI, Hiroyuki TODA
  • Patent number: 11040087
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: June 22, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY, OSAKA PREFECTURAL HOSPITAL ORGANIZATION
    Inventors: Tatsushi Toda, Kazuhiro Kobayashi, Motoi Kanagawa, Tamao Endo, Hiroshi Manya, Yoshinao Wada, Michiko Tajiri
  • Publication number: 20200188491
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 18, 2020
    Inventors: Tatsushi TODA, Kazuhiro KOBAYASHI, Motoi KANAGAWA, Tamao ENDO, Hiroshi MANYA, Yoshinao WADA, Michiko TAJIRI